⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

February 4, 2026Expert Review of Gastroenterology & Hepatology

Leucine-rich alpha-2 glycoprotein as a blood biomarker in Inflammatory bowel disease: clinical implications and future perspectives

Yuichi Morohoshi

View Full Paper

Ask AI

Bookmark

Share

Key Points

The research aims to evaluate leucine-rich alpha-2 glycoprotein as a biomarker for inflammation in inflammatory bowel disease.
Assess correlations between LRG levels and mucosal or transmural inflammation.
Examine sensitivity of LRG in biologic-treated patients and those with normal CRP.
Evaluate rapid turnaround time for LRG testing under treat-to-target strategies.
LRG shows strong correlation with inflammation across IBD phenotypes.
Retains sensitivity even in treated patients or those with normal CRP levels.
Predicts treatment response effectively for individualized care.

Implication

Observational evidence correlates a blood biomarker with treatment response in inflammatory bowel disease, suggesting enhanced precision care.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Yuichi Morohoshi (2026) studied this question.

synapsesocial.com/papers/6988270a0fc35cd7a8845f02 https://doi.org/10.1080/17474124.2026.2628012

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Evaluation of Serum Leucine-Rich α2-Glycoprotein Levels in Inflammatory Bowel Disease Patients Across Racial Groups2025
2Leucine-rich alpha-2 glycoprotein is useful in predicting clinical relapse in patients with Crohn’s disease during biological remission2024 · 3 citations
3Leucine Rich Glycoprotein as a biomarker In Ulcerative Colitis Disease2024
4Clinical utility of serum leucine-rich alpha-2 glycoprotein for assessing disease activity and mucosal healing in ulcerative colitis across different treatment settings: a prospective observational cohort studyCohort Study · 2026
5Leucine-Rich Alpha-2 Glycoprotein 1 as a Biomarker for Evaluation of Inflammatory Bowel Disease Activity in Childrencohort · 2025 · 3 citations